Apogee Therapeutics, Inc. entered into a merger agreement with Andor LLC and AbbVie Inc. to be acquired in a cash transaction for $135.11 per share. The deal is subject to stockholder approval and regulatory clearances. Apogee Therapeutics, Inc. is a biotechnology company focused on developing novel therapeutics.

On June 17, 2026, Apogee Therapeutics entered into an antibody discovery agreement and a contemporaneous license agreement with Paragon Therapeutics, Inc. Paragon will generate and characterize monospecific antibody candidates directed to interleukin 31 receptor (IL-31R), with Apogee paying monthly research fees and potential CMC activity fees between $1.3 million and $2.0 million. Apogee acquired an exclusive, worldwide, royalty-bearing license to exploit antibodies discovered under the agreement, with potential milestone payments to Paragon totaling up to $23.25 million, including $5.25 million upon the first human dose in a Phase I trial. The agreement includes low-single digit royalties on net sales. Apogee operates in the biotechnology industry and develops therapeutic antibodies.